Complement Component C3a Antibody (354113) [Alexa Fluor® 647]

• Reactivity: Hu
• Applications: WB
• Clone: 354113
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Alexa Fluor 647

Complement Component C3a Antibody (354113) [Alexa Fluor® 647] Summary

• Immunogen: E. coli-derived recombinant human Complement Component C3a
  Ser672-Arg748
  Accession # P01024
• Specificity: Detects human Complement Component C3a in direct ELISAs and Western blots. In direct ELISAs and Western blots, no cross-reactivity with recombinant human (rh) Complement Component C5a or rhComplement Component C3d is observed.
• Source: N/A
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Purity Statement: Protein A or G purified from hybridoma culture supernatant

Applications/Dilutions

• Dilutions:
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2 mg/mL in a saline solution containing BSA and Sodium Azide.

Notes

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Complement Component C3a Antibody (354113) [Alexa Fluor® 647]

• AHUS5;ARMD9;ASP;C3a;C3b;Complement C3;CPAMD1;HEL-S-62p
• Anaphylatoxin
• C3
• Complement Component C3a

Background

C3a is an anaphylotoxin polypeptide comprising amino acids (aa) 672‑748 of the Complement C3 precursor protein (1‑4). Anaphylatoxins are proteolytically generated from the C3, C4 and C5 alpha chains by convertases formed by other complement fragments (2). They share 30‑36% aa identity, and mediate inflammatory responses that vary in strength in the order C5a > C3a > C4a (2). Like C4a and C5a, the 77 aa, 9 kDa human C3a contains six conserved cysteine residues that form a knot structure and possess an overall basic charge (4, 5). It is not glycosylated (4). The C-terminal regions of C3a and C4a, but not C5a, shows antimicrobial activity (5). Human C3a shows 67‑69% aa identity with mouse, rat, guinea pig, bovine, porcine and canine C3a. C3a formation is common to all three pathways of complement activation: classical (antibody-mediated), lectin and alternative (1, 2). It binds the G-protein coupled C3a receptor (C3aR) on myeloid peripheral blood leukocytes, and on activated lymphocytes, endothelial and internal organ epithelial cells (7, 10). C3a contributes to both innate and adaptive immunity. It activates mast cells and neutrophils, triggering robust mast cell degranulation in airways during asthmatic allergen challenges (9). It enhances lipopolysaccharide-induced prostaglandin, cytokine and chemokine secretion by macrophages and other cells (1, 6‑8). It assists in Th2-type inflammatory reactions and stimulates smooth muscle contraction and leukocyte chemotaxis (8, 9). Endogenous carboxypeptidase-N can remove the arginine at the C-terminus of the anaphylatoxins to create desArg forms (1). C3adesArg, also called ASP (Acylation-Stimulating Protein) is an adipocyte-derived protein that binds the C5L2 (GPR77) receptor and stimulates adipose tissue triglyceride synthesis (2, 10, 11). The anaphylactic activity of ASP is weaker than that of C3a (6, 10). C5L2 is also involved in C3a and C5a activity (11).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Bioinformatics

• Uniprot:
  • P01024()